Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiphospholipid antibody: future developments

M D Lockshin1

  • 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892.

Lupus
|August 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal evaluation of diffusion tensor imaging and cognition in systemic lupus erythematosus.

Lupus·2018
Same author

Functional Magnetic Resonance Imaging of Working Memory and Executive Dysfunction in Systemic Lupus Erythematosus and Antiphospholipid Antibody-Positive Patients.

Arthritis care & research·2016
Same author

Assisted reproductive technology in SLE and APS.

Lupus·2014
Same author

Site differences in mild cognitive dysfunction (MCD) among patients with systemic lupus erythematosus (SLE).

Lupus·2012
Same author

Antiphospholipid: to test, or not to test, that is the question.

International journal of clinical practice·2012
Same author

APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking.

Lupus·2012
Same journal

Association of systemic lupus erythematosus with 90-day readmission following heart failure hospitalization: A national readmission database (NRD) analysis, 2016-2017.

Lupus·2026
Same journal

Association of GPX4 rs713041 and rs4807542 polymorphisms and serum GPX4 levels in Chinese patients with systemic lupus erythematosus.

Lupus·2026
Same journal

Giant cell myocarditis in an 18-year-old patient with new-onset systemic lupus erythematosus: A fatal case of rapidly progressing heart failure.

Lupus·2026
Same journal

An evidence-based specialist nursing protocol for children with hypoprothrombinemia-lupus anticoagulant syndrome (HLAS) and its application research.

Lupus·2026
Same journal

T-bet expression in B cell subsets: Association with T peripheral helper cells and clinical activity in systemic lupus erythematosus.

Lupus·2026
Same journal

Autonomic dysfunction in systemic lupus erythematosus and systemic sclerosis.

Lupus·2026
See all related articles

Antiphospholipid antibodies (aPL) research has advanced, with beta 2-glycoprotein I identified as a key antigen component. Further studies are needed to understand aPL syndrome genetics and optimize patient treatment strategies.

Area of Science:

  • Immunology
  • Hematology
  • Rheumatology

Background:

  • An NIH workshop in 1991 highlighted key research questions regarding antiphospholipid antibodies (aPL).
  • Significant progress has been made in understanding the molecular and biological aspects of aPL since 1991.
  • Partial answers have emerged regarding the antigen, pathogenesis, and animal models for aPL-related conditions.

Purpose of the Study:

  • To review the progress made in understanding antiphospholipid antibodies (aPL) since a 1991 NIH workshop.
  • To identify critical unknowns and outline a future research agenda for the aPL syndrome.
  • To assess the current state of clinical studies, risk prediction, and treatment trials for aPL-associated diseases.

Main Methods:

  • Review of molecular and biological aspects of antiphospholipid antibodies (aPL).

Related Experiment Videos

  • Analysis of progress in understanding antigenicity, pathogenesis, and animal models.
  • Evaluation of clinical studies, risk prediction, and therapeutic interventions.

    • Main Results:

    • Beta 2-glycoprotein I is identified as an obligatory component of the antigen.
    • Abnormal coagulation is considered the probable central pathogenic event in the aPL syndrome.
    • Existing animal models provide tools for further investigation.

    Conclusions:

    • Critical unknowns remain, including the genetics of the aPL syndrome and the precise mechanisms of pathogenesis.
    • Risk prediction and the development of effective, evidence-based treatment strategies require further investigation.
    • Despite ongoing questions, current therapies allow for the conduct of important prospective clinical trials.